论文部分内容阅读
A major advance was made to reduce the side effects of cancer therapy via the elucidation of the tumor-specific lytic path“hyperploid progression-mediated death”targeting retinoblastoma(Rb)or p53-mutants defective in G1 DNA damage checkpoint.The genetic b